Physician profile
Susan E Peck
NPI 1104852169
$1,762.20
in general payments reported to CMS, 2019-2025
23 companies · $60.69 in 2025
The $60.69 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $292 · 2021: $238 · 2022: $289 · 2023: $324 · 2024: $26.35 · 2025: $60.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.68 | 2019-2024 | |
| Therapeuticsmd, INC. | $239.53 | 2019-2022 | |
| Amgen INC. | $122.09 | 2020 | |
| Evofem Biosciences, INC. | $92.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.54 | 2020-2023 | |
| Hologic Sales and Service, LLC | $69.69 | 2020-2022 | |
| Gilead Sciences, INC. | $60.69 | 2025 | |
| Organon LLC | $52.57 | 2021-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $51.00 | 2020-2023 | Gardasil 9 |
| Coopersurgical, INC. | $47.57 | 2019-2023 | Paragard T 380a |
| Exeltis, USA INC. | $41.55 | 2022-2023 | Slynd |
| Myovant Sciences INC. | $38.15 | 2021 | |
| Mayne Pharma Commercial LLC | $28.00 | 2022-2023 | |
| Astellas Pharma US INC | $24.90 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $20.25 | 2023 | Myfembree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $18.88 | 2021 | |
| Allergan, INC. | $18.22 | 2019 | |
| Agile Therapeutics, INC. | $17.38 | 2021 | |
| Novo Nordisk INC | $14.92 | 2023 | Wegovy |
| Amag Pharmaceuticals, INC. | $14.46 | 2019 | |
| Covidien LP | $14.24 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.63 | 2019 | |
| Lupin INC. | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.